Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roosha Parikh

Cardiovascular Disease Roslyn, NY Medical Doctor

NPI 1043560626 CMS profile 1380332

100 Port Washington Blvd, Roslyn, NY 11576

Open in the dashboard

General payments

$72,781

132 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roosha Parikh of Roslyn, NY is reported in the CMS Open Payments database as having received $72,781 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $55,974 67
2024 General $12,317 12
2023 General $2,456 12
2022 General $809 8
2020 General $253 10
2019 General $972 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roosha Parikh
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Roosha Parikh were reported at $55,974. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Roosha Parikh Cardiovascular Disease median Middle half National median
2019 $972 $450 $127–$1,392 $163
2020 $253 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $809 $395 $121–$1,211 $149
2023 $2,456 $443 $136–$1,283 $160
2024 $12,317 $450 $136–$1,323 $164
2025 $55,974 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. HeartFlow, Inc. $67,861 67 payments
  2. Siemens Medical Solutions USA, Inc. $1,737 2 payments
  3. Medtronic, Inc. $916 9 payments
  4. Boston Scientific Corporation $758 5 payments
  5. Amgen Inc. $488 22 payments
  6. Abbott Laboratories $315 7 payments
  7. Cleerly, Inc. $162 3 payments
  8. Edwards Lifesciences Corporation $114 2 payments
  9. Philips Electronics North America Corporation $111 2 payments
  10. Recor Medical Inc $108 1 payment
  11. Other $211 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $58,540 17 payments
  2. Travel and Lodging $7,315 23 payments
  3. Food and Beverage $4,313 86 payments
  4. Consulting Fee $2,113 5 payments
  5. Grant $500 1 payment
Products named General payments · program years 2019–2025
  1. FFRct $67,861 67 payments
  2. COREVALVE EVOLUT R $634 5 payments
  3. GENERAL STRUCTURAL HEART $500 1 payment
  4. Repatha $488 22 payments
  5. SYMPLICITY G3 $183 2 payments
  6. Cleerly Labs $162 3 payments
  7. Cleerly Ischemia $162 3 payments
  8. AVVIGO Guidance System $161 1 payment
  9. AMPLATZER $150 3 payments
  10. IGT Devices Undivided $111 2 payments
  11. Other $819 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$66,963

Medicare's payments for the services billed

Medicare patients

821

Average age 78

Services billed

1,279

384 women, 437 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 60%
Heart failure 49%
Atrial fibrillation 49%
Diabetes 44%
Chronic kidney disease 33%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record